Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

WGRX - Wellgistics Health, Inc. Latest News | Finranks

Home

WGRX

W

Wellgistics Health, Inc. (WGRX)

NCM – Real Time Price. Currency in USD

0.10

-0.01 (-9.17%)

At close: Mar 27, 2026, 4:00 PM EDT

0.10

+0.00 (1.39%)

After-hours: Mar 27, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Why Are Shares Of Wellgistics Health Falling?

Why Are Shares Of Wellgistics Health Falling?

Despite the positive news, investors are concerned that the acquisition may not be enough to turn around the negative revenue growth Wellgistics experienced in the last year. Revenue fell about half between the last two quarters, going from $7 million to $3 million.

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business.

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.

Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction

Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction

TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders. The prescription drug and broader healthcare landscapes in the United States are rapidly changing.

Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities

Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities

Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company1 TAMPA, FL / ACCESS Newswire / March 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers, partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows companies that engage in the distribution of medical products and services to know whether a particular product or service is covered by a patient's insurance carrier and the level of coverage that patient has.

Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)

Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301 Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs.

Wellgistics Health Selects Top Five Blockchain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization Mandate

Wellgistics Health Selects Top Five Blockchain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization Mandate

Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain platforms to build PharmacyChain™ U.S. prescription drugs market project to grow from $634 billion market to $883 billion by 2030 according to Grandview Research[1] Global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, according to Grandview Research[2] TAMPA, FLORIDA / ACCESS Newswire / March 5, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that it has completed its evaluation process to select the most suitable blockchain platforms on which to build smart contracts-enabled pharmaceutical drug tracking system PharmacyChain that will further enable industry-wide serialization mandates, such as the United States' Drug Supply Chain Security Act (DSCSA[3]). The Company selected Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu and Corda (R3) as the most suitable blockchain platforms currently in use in order to initiate PharmacyChain development.

Videos

No Data

There is no data to display

Press releases

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

TAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business.

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ , today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.

Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction

Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction

TAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders. The prescription drug and broader healthcare landscapes in the United States are rapidly changing.

Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities

Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities

Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company1 TAMPA, FL / ACCESS Newswire / March 11, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain for providers, partners and pharmacies in order to facilitate its faster adoption into the US healthcare ecosystem. EBV is crucial because it allows companies that engage in the distribution of medical products and services to know whether a particular product or service is covered by a patient's insurance carrier and the level of coverage that patient has.